Bibliography
- YAGODA A, PETRYLAK D: Cytotoxic chemotherapy for advanced hormone- refractory prostate cancer. Cancer (1993) 71:1098–1103.
- SLACK NH, MURPHY GP: A decade of experience with chemotherapy for prostate cancer. Urology (1983) 22:1–5.
- EISENBERGER MA: Chemotherapy for prostate cancer. NCI Monographs (1988) 7:151–162.
- CLARK PI, SLEVIN ML: The clinical pharmacology of etoposide and teniposide. Clin. Pharmacokin. (1987) 12:223–228.
- HANDE KR, KROZLEY MG, GRECO FA et al.: Bioavailability of low-dose oral etoposide. J. Clin. Oncol. (1993) 11:374–379.
- STEWART CF, ARBUCK SG, PIEPER JA et al.: Altered protein binding of etoposide in patients with cancer. Clin. Pharmacol. Ther. (1989) 45:49–53.
- STEWART CF, ARBUCK SG, FLEMING RA et al: Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin. Pharmacol. Ther. (1991) 50:385–390.
- JOEL SP, SHAH R, SLEVIN ML: Etoposide dosage and pharmacodynamics. Cancer Chemother. Pharmacol. (1994) 34:S69–76.
- SMITH MA, RUBINSTEIN L, ANDERSON JR et al.: Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J. Clin. Oncol. (1999) 17:569–577.
- WALTHER PJ, WILLIAMS SD, TRONER M, GRECO FA, BIRCH R, EINHORN LW: Phase II study of etoposide for carcinoma of the prostate. Cancer Treat. Rep. (1986) 70:771–772.
- SCHER HI, STERNBERG C, HESTON WDW et al.: Etoposide in prostatic cancer: experimental studies and Phase II trial in patients with bidimensionally measurable disease. Cancer Chemother. Pharmacol. (1986) 18:24–26.
- TRUMP DL, LOPRINZI CL: Phase II trial of etoposide in advanced prostate cancer. Cancer Treat. Rep. (1984) 68:1195–1198.
- HUSSAIN MH, PIENTA KJ, REDMAN BG, CUMMINGS GD,FLAHERTY LE: Oral etoposide in the treatment of hormone-refractory prostate cancer. Cancer (1994) 74:100–103.
- PIENTA KJ, LEHR JE: Inhibition of prostate cancergrowth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J. UroL (1993) 149:1622–1625.
- PIENTA KJ, REDMAN B, HUSSAIN M et al.: Phase II evalua-tion of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. Clin. Oncol. (1994) 12:2005–2012.
- PIENTA KJ, REDMAN BG, BANDEKAR R et al.: A Phase IItrial of estramustine and oral etoposide in hormone refractory prostate cancer. Urology (1997) 50:401–407.
- DIMOPOULOS MA, PANOPOULOS C, BAMIA C et al.: Oral estramustine and oral etoposide for hormone refrac-tory prostate cancer. Urology (1997) 50:754–758.
- SMITH DC, DUNN RL, STRAWDERMAN MS, PIENTA KJ: Change in serum prostate specific antigen as a marker of response to cytotoxic therapy for hormone- refrac-tory prostate cancer. J. Clin. Oncol (1998) 16:1835–1843.
- ••Up-to-date description of how PSA can be used as aprognostic marker in hormone refractory prostate cancer.
- MAULARD-DURDUX C, DUFOUR B, HENNEQUIN C, CHRETIEN Y, DELANIAN S, HOUSSET M: Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer (1996) 77:1144–1148.
- NAITO S, UEDA T, KOTOH S et al.: Treatment ofadvanced hormone refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin. Cancer Chemother. Pharmacol. (1995) 35:225–229.
- FUSE H, MURAISHI Y, FUJISHIRO Y, KATAYAMA T: Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer. Int. Urol. Nephrol. (1996) 28:79–85.
- MILLMAN R, LOGOTHETIS C: Update of the NCCN guidelines for the treatment of prostate cancer. Oncology (1997) 11:180–193.
- ••Review of the current guidelines for treating prostate cancer.